Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

导出 OA

翻译打印收藏纠错

作者： Georgina,Nakafero ^[1] ; Matthew J,Grainge ^[2] ; Tim,Card ^[2] ; Maarten W,Taal ^[3] ; Guruprasad P,Aithal ^[4] ; Weiya,Zhang ^[3] ; Michael,Doherty ^[5] ; Christopher P,Fox ^[1] ; Christian D,Mallen ^[1] ; Abhishek,Abhishek ^[6]

作者单位： Academic Rheumatology. ^[1] Population and Lifespan Sciences. ^[2] Nottingham Digestive Diseases Centre, School of Medicine. ^[3] Centre for Kidney Research and Innovation, University on Nottingham. ^[4] NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham. ^[5] Department of Haematology, Nottingham University Hospital NHS Trust, Nottingham. ^[6] Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Keele, UK. ^[7]

关键词 drug toxicity leflunomide monitoring psoriatic arthritis rheumatoid arthritis

主题词队列研究(Cohort Studies);血液学试验(Hematologic Tests);人类(Humans);预后(Prognosis)

DOI 10.1093/rheumatology/keab790

PMID 34718430

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交